Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage III Adrenal Cortical Carcinoma AJCC v8”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Looking for participantsNCT06900595
What this trial is testing

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Who this might be right for
Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical Carcinoma+3 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Study completedNCT03370718
What this trial is testing

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Who this might be right for
Metastatic Carcinoma in the Adrenal CortexStage III Adrenal Cortex Carcinoma AJCC v8Stage IV Adrenal Cortex Carcinoma AJCC v8+1 more
M.D. Anderson Cancer Center 18
Early research (Phase 1)Looking for participantsNCT04119024
What this trial is testing

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more
Anusha Kalbasi 18
Testing effectiveness (Phase 2)Looking for participantsNCT06006013
What this trial is testing

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Who this might be right for
Locally Advanced Adrenal Cortex CarcinomaAdrenal Cortical CarcinomaStage III Adrenal Cortex Carcinoma+2 more
Emory University 21